NASDAQ:RGLS

Regulus Therapeutics News Headlines

$1.29
-0.11 (-7.86 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$1.22
Now: $1.29
$1.38
50-Day Range
$1.15
MA: $1.51
$1.96
52-Week Range
$0.42
Now: $1.29
$2.32
Volume1.70 million shs
Average Volume3.04 million shs
Market Capitalization$93.53 million
P/E RatioN/A
Dividend YieldN/A
Beta2.41

Headlines

Regulus Therapeutics (NASDAQ RGLS) News Headlines Today

SourceHeadline
Regulus Therapeutics (NASDAQ:RGLS) Stock Price Passes Above 200-Day Moving Average of $1.12Regulus Therapeutics (NASDAQ:RGLS) Stock Price Passes Above 200-Day Moving Average of $1.12
americanbankingnews.com - April 16 at 1:00 AM
Regulus Therapeutics Announces Completion of Dosing in the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)Regulus Therapeutics Announces Completion of Dosing in the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
finance.yahoo.com - April 15 at 8:15 AM
Regulus Therapeutics Inc. (NASDAQ:RGLS) Short Interest Up 61.8% in MarchRegulus Therapeutics Inc. (NASDAQ:RGLS) Short Interest Up 61.8% in March
americanbankingnews.com - March 31 at 4:58 AM
Regulus Therapeutics (NASDAQ:RGLS) Stock Price Crosses Above 200 Day Moving Average of $1.02Regulus Therapeutics (NASDAQ:RGLS) Stock Price Crosses Above 200 Day Moving Average of $1.02
americanbankingnews.com - March 26 at 2:24 AM
Investors Who Bought Regulus Therapeutics (NASDAQ:RGLS) Shares A Year Ago Are Now Up 101%Investors Who Bought Regulus Therapeutics (NASDAQ:RGLS) Shares A Year Ago Are Now Up 101%
finance.yahoo.com - March 10 at 2:24 PM
Regulus: Q4 Earnings SnapshotRegulus: Q4 Earnings Snapshot
finance.yahoo.com - March 9 at 10:23 PM
Will Regulus (RGLS) Report Negative Q4 Earnings? What You Should KnowWill Regulus (RGLS) Report Negative Q4 Earnings? What You Should Know
finance.yahoo.com - March 4 at 6:58 PM
Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
finance.yahoo.com - February 10 at 8:35 AM
Regulus Announces Addition to Board of DirectorsRegulus Announces Addition to Board of Directors
finance.yahoo.com - January 27 at 12:28 PM
Regulus Therapeutics to Present at the H.C. Wainwright Virtual BioConnect ConferenceRegulus Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
finance.yahoo.com - January 5 at 12:48 PM
Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock?Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock?
finance.yahoo.com - December 9 at 12:50 PM
Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock?Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock?
finance.yahoo.com - December 9 at 12:50 PM
Regulus Therapeutics Announces Closing of $19.4 Million Private Placement of EquityRegulus Therapeutics Announces Closing of $19.4 Million Private Placement of Equity
finance.yahoo.com - December 8 at 9:38 AM
Regulus Therapeutics Collaborates With Bio-Techne For Biomarker DevelopmentRegulus Therapeutics Collaborates With Bio-Techne For Biomarker Development
finance.yahoo.com - December 2 at 7:13 AM
Regulus Therapeutics Reports Third Quarter 2020 Financial Results and Recent UpdatesRegulus Therapeutics Reports Third Quarter 2020 Financial Results and Recent Updates
finance.yahoo.com - November 5 at 6:59 PM
Regulus (RGLS) Reports Q3 Loss, Tops Revenue EstimatesRegulus (RGLS) Reports Q3 Loss, Tops Revenue Estimates
finance.yahoo.com - November 5 at 6:59 PM
Regulus Therapeutics Announces Achievement of Interim Enrollment Milestone Under Collaboration with SanofiRegulus Therapeutics Announces Achievement of Interim Enrollment Milestone Under Collaboration with Sanofi
finance.yahoo.com - November 2 at 11:58 AM
Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
finance.yahoo.com - October 19 at 2:08 PM
Regulus Therapeutics IncRegulus Therapeutics Inc
bloomberg.com - October 18 at 12:07 AM
Dosing underway in Regulus Therapeutics RGLS4326 study for kidney diseaseDosing underway in Regulus Therapeutics' RGLS4326 study for kidney disease
seekingalpha.com - October 15 at 9:25 AM
Regulus announces receipt of milestone payment from SanofiRegulus announces receipt of milestone payment from Sanofi
seekingalpha.com - October 13 at 5:22 PM
Regulus Therapeutics (RGLS) Presents at Wells Fargo Securities 2020 Virtual Healthcare Conference - SlideshowRegulus Therapeutics (RGLS) Presents at Wells Fargo Securities 2020 Virtual Healthcare Conference - Slideshow
seekingalpha.com - September 11 at 9:07 PM
Regulus Therapeutics to Present at the H.C. Wainwright 22nd Annual Virtual Global Investment ConferenceRegulus Therapeutics to Present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference
finance.yahoo.com - September 11 at 11:04 AM
Regulus Therapeutics to Present at the 2020 Wells Fargo Virtual Healthcare ConferenceRegulus Therapeutics to Present at the 2020 Wells Fargo Virtual Healthcare Conference
finance.yahoo.com - September 3 at 10:27 AM
Regulus Therapeutics restructures agreements with Sanofi and Oxford FinanceRegulus Therapeutics restructures agreements with Sanofi and Oxford Finance
seekingalpha.com - August 31 at 11:24 AM
Regulus Therapeutics EPS misses by $0.12Regulus Therapeutics EPS misses by $0.12
seekingalpha.com - August 13 at 8:02 PM
Regulus Therapeutics Reports Second Quarter 2020 Financial Results and Recent UpdatesRegulus Therapeutics Reports Second Quarter 2020 Financial Results and Recent Updates
finance.yahoo.com - August 13 at 8:02 PM
Regulus (RGLS) Reports Q2 Loss, Lags Revenue EstimatesRegulus (RGLS) Reports Q2 Loss, Lags Revenue Estimates
finance.yahoo.com - August 13 at 8:02 PM
Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseRegulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
finance.yahoo.com - August 6 at 3:33 PM
Regulus Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual ConferenceRegulus Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
finance.yahoo.com - August 6 at 10:31 AM
Regulus Therapeutics Appoints Denis Drygin, Ph.D., as Chief Scientific OfficerRegulus Therapeutics Appoints Denis Drygin, Ph.D., as Chief Scientific Officer
finance.yahoo.com - August 3 at 8:36 AM
Regulus RGLS4326 an Orphan Drug in U.S. for rare kidney disorderRegulus' RGLS4326 an Orphan Drug in U.S. for rare kidney disorder
seekingalpha.com - July 29 at 2:42 PM
Regulus Therapeutics +17% on US Orphan Drug tag for RGLS4326 in kidney diseaseRegulus Therapeutics +17% on US Orphan Drug tag for RGLS4326 in kidney disease
seekingalpha.com - July 29 at 9:42 AM
Regulus Therapeutics Announces FDA Orphan Drug Designation of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)Regulus Therapeutics Announces FDA Orphan Drug Designation of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
finance.yahoo.com - July 29 at 9:42 AM
Regulus Therapeutics concludes early-stage study of RGLS4326 in genetic kidney diseaseRegulus Therapeutics concludes early-stage study of RGLS4326 in genetic kidney disease
seekingalpha.com - July 22 at 12:04 PM
Regulus Therapeutics Completes Dosing in Phase 1 Multiple Ascending Dose Study of RGLS4326 in Healthy Volunteers for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)Regulus Therapeutics Completes Dosing in Phase 1 Multiple Ascending Dose Study of RGLS4326 in Healthy Volunteers for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
finance.yahoo.com - July 22 at 12:04 PM
Analysts Revenue Estimates For Regulus Therapeutics Inc. (NASDAQ:RGLS) Are Surging HigherAnalysts' Revenue Estimates For Regulus Therapeutics Inc. (NASDAQ:RGLS) Are Surging Higher
finance.yahoo.com - June 12 at 12:37 PM
Regulus Therapeutics Inc.Regulus Therapeutics Inc.
www.barrons.com - May 14 at 5:37 PM
Regulus Therapeutics EPS misses by $0.13Regulus Therapeutics EPS misses by $0.13
seekingalpha.com - May 14 at 5:37 PM
Regulus Therapeutics Reports First Quarter 2020 Financial Results and Recent UpdatesRegulus Therapeutics Reports First Quarter 2020 Financial Results and Recent Updates
finance.yahoo.com - May 14 at 5:37 PM
RGLS Regulus Therapeutics Inc. Common StockRGLS Regulus Therapeutics Inc. Common Stock
www.nasdaq.com - May 7 at 6:23 PM
Regulus (RGLS) Expected to Beat Earnings Estimates: Should You Buy?Regulus (RGLS) Expected to Beat Earnings Estimates: Should You Buy?
finance.yahoo.com - May 7 at 1:22 PM
Regulus Therapeutics EPS beats by $0.01, beats on revenueRegulus Therapeutics EPS beats by $0.01, beats on revenue
seekingalpha.com - March 12 at 7:01 PM
Regulus Reports Fourth Quarter and Year-End 2019 Financial Results and Recent UpdatesRegulus Reports Fourth Quarter and Year-End 2019 Financial Results and Recent Updates
finance.yahoo.com - March 12 at 7:01 PM
Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseRegulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
finance.yahoo.com - March 9 at 1:12 PM
BRIEF-Regulus Therapeutics Reinitiates Multiple Ascending Dose Study Of RGLS4326 For The Treatment Of ADPKDBRIEF-Regulus Therapeutics Reinitiates Multiple Ascending Dose Study Of RGLS4326 For The Treatment Of ADPKD
uk.reuters.com - February 13 at 8:00 PM
Regulus Therapeutics Reinitiates Multiple Ascending Dose Study of RGLS4326 for the Treatment of ADPKDRegulus Therapeutics Reinitiates Multiple Ascending Dose Study of RGLS4326 for the Treatment of ADPKD
finance.yahoo.com - February 13 at 8:00 PM
Regulus Therapeutics Inc. Common Stock (RGLS) Insider ActivityRegulus Therapeutics Inc. Common Stock (RGLS) Insider Activity
www.nasdaq.com - February 13 at 12:48 AM
How Regulus Therapeutics Inc. (NASDAQ:RGLS) Can Impact Your Portfolio VolatilityHow Regulus Therapeutics Inc. (NASDAQ:RGLS) Can Impact Your Portfolio Volatility
finance.yahoo.com - January 21 at 5:52 PM
Hedge Funds Are Dumping Regulus Therapeutics Inc (RGLS)Hedge Funds Are Dumping Regulus Therapeutics Inc (RGLS)
finance.yahoo.com - December 23 at 12:10 AM
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.